Glioblastoma (GBM), the most aggressive and common primary brain tumor, presents significant therapeutic challenges due to its inherent resistance to conventional treatments, such as radiotherapy and chemotherapy, and its diffuse infiltration into brain tissue, which precludes complete surgical resection. A profound understanding of the processes underlying GBM cell migration and invasion within a physiological microenvironment is crucial for developing more effective therapeutic strategies. In this thesis, an innovative methodology that combines adult organotypic brain tissue slice culture (OTC) and light-sheet fluorescence microscopy (LSFM) of cleared tissues, termed OTCxLSFM was developed. This combined technique enables high-resolution, three-dimensional visualization of GBM tissue infiltration at a single-cell level, providing detailed morphological insights into tumor cells. Using the OTCxLSFM methodology, it was demonstrated that GBM tissue infiltration can be effectively inhibited through various interventions. Specifically, genetic depletion of the tetraspanin transmembrane receptor CD9 or the signal transducer and activator of transcription 3 (STAT3), or treatments with arsenic trioxide (ATO) or the JAK2/STAT3 inhibitor WP1066, significantly reduced tumor cell infiltration. These findings highlight the potential of targeting specific molecular pathways to interfere GBM progression. Furthermore, preliminary research has identified BRCA1-associated ATM -activator 1 (BRAT1) as a crucial factor in the pathogenesis of GBM. BRAT1 drives key aspects of GBM characteristics, including the DNA damage response (DDR) and tumor cell migration. For this purpose, a stable depletion of BRAT1 was established in adherent GBM cells. To analyze the subpopulation within GBM tumors, stem cell-like (GSC) GBM tumor spheres, which express typical stem cell markers, were additionally used. The stable BRAT1 depletion in both cell models led to impaired DNA repair of DNA double-strand breaks (DSB) and increased radiation sensitivity in vitro. Furthermore, the BRAT1 depletion significantly inhibited tumor growth and invasion, which were corroborated by both in vitro and in vivo studies. In orthotopic mouse models, transplantation of BRAT1-depleted GSCs resulted in significantly extended overall survival. Preliminary proteomic analysis revealed that a substantial proportion of downregulated proteins in BRAT1-depleted cells are associated with cell migration and invasion, underscoring BRAT1's role in these processes. Importantly, the OTCxLSFM technique was successfully applied to study the effects of BRAT1 inhibition in GBM, by treating GSCs with the BRAT1 inhibitor Curcusone D (CurD), which significantly impeded cell migration and invasion. The migration and invasion of GBM cells and GSCs was also inhibited in in vitro assays using CurD. In addition, CurD particularly when combined with irradiation, led to a synergistic inhibition of tumor growth and infiltration in an ex vivo model using GSCs, further validating the potential of BRAT1 as a new therapeutic target. In conclusion, the OTCxLSFM methodology provides a powerful tool for investigating the complex mechanisms of GBM infiltration and identifying potential therapeutic targets. These findings establish BRAT1 as a promising target for GBM treatment and highlight CurD as a candidate for targeted therapy development. This approach holds significant promise for improving therapeutic outcomes in patients with this aggressive and challenging disease.